-
Mov Disord: Parkinson's patients have rapid eye movements at the same time, and the clinical progress is faster
Time of Update: 2021-09-29
Parkinson's disease + pRBD patients progress faster in motor, mood, and cognitive symptoms Original Source: Liu Y, Lawton MA, Lo C, et al.
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder : The Oxford Discovery Cohort Study.
-
Mov Disord-After ten years of follow-up, how does the movement, cognition and imaging of Huntington patients change?
Time of Update: 2021-08-14
In addition, combining these data sets can capture a wider range of disease progression fragments (for example, although IMAGE and TRACK have a small number of participants in group 1, PREDICT provides the same larger sample of participants), so it can improve characterization Range .
-
Mov Disord: A number of common blood markers can be used for early Parkinson's disease surveillance
Time of Update: 2022-10-25
analyzed well-characterized new-onset PD (DeNoPa) patient cohorts and matched HCs Different combinations of markers in longitudinal samples, assessing established markers of neuronal function, inflammation, and cardiovascular risk in deep phenotypic PD by high-throughput sandwich immune multiplex combinations.
-
Mov Disord.: 7T MRI found impaired structural connectivity between brainstem nuclei in patients with REM sleep behavior disorder
Time of Update: 2022-01-22
The brainstem pathophysiological basis of REM sleep behavior disorder has been described in animal models, but has not been adequately studied in humans due to the lack of in vivo brainstem nuclear atlas and limited magnetic resonance imaging (MRI) sensitivity .
-
Mov Disord: DTI study found that free water in the dorsal medial nucleus of the thalamus is associated with cognitive decline in Parkinson's disease
Time of Update: 2022-01-08
Mov DisordThis study assessed whether the FW of the thalamus is mainly involved in cognitive functions (ie, the dorsal medial nucleus and pronucleus), whether Meynert basal nucleus (nbM) and the hippocampus are associated with longitudinal cognitive decline, and distinguished the baseline cognition of patients with early Parkinson's disease Status .
-
Mov. Disord: APOE ε4 affects the progression of Parkinson's disease
Time of Update: 2021-12-03
Disord and analyzed whether APOE ε4 contributes to the progression of early Parkinson's disease (PD) .
Disord and analyzed whether APOE ε4 contributes to the progression of early Parkinson's disease (PD) .
-
Mov Disord: Is it possible to suffer from Parkinson's, check glutathione and take a look
Time of Update: 2021-11-13
diagnosisOriginal sourcePlasma Glutathione and Prodromal Parkinson's Disease Probability [published online ahead of print, 2021 Oct 25].
28826Plasma Glutathione and Prodromal Parkinson's Disease Probability [published online ahead of print, 2021 Oct 25].
28826 Plasma Glutathione and Prodromal Parkinson's Disease Probability [published online ahead of print .
-
Mov Disord: Neurofilament light chain can predict the disease severity and progression of multiple system atrophy
Time of Update: 2021-11-13
In summary, the baseline plasma NFL level was significantly correlated with the severity and progression of exercise in MSA patients (P<0.
28847 Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy [published online ahead of print, 2021 Oct 31] Mov Disord 2021; 10.
-
Mov Disord: Spinocerebellar ataxia type 3 severity is related to lifestyle
Time of Update: 2021-11-13
The study collected data on smoking, drinking, physical activity, physical therapy, and body mass index (BMI) of 243 SCA3 patients and 119 control groups to detect their correlation with age of onset, disease severity, and progression .
-
Mov Disord: Parkinson's disease, ApoE may lead to the progression of dyskinesia
Time of Update: 2021-11-12
However, the relationship between lipoprotein E (APOE) ε4 and the movement progression of patients with Parkinson's disease is still unknown .
Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease .
-
Mov Disord: Genetic risk score helps stratify Parkinson's disease
Time of Update: 2021-11-12
The study proved the feasibility of the PD polygenic hazard approach, integrating genetic influences on disease risk and age of onset in a model .
This study proved the feasibility of the PD polygenic hazard method, integrating the genetic influence on disease risk and age of onset in a model .
-
Mov Disord: The later the menopause, the lower the prevalence of Parkinson's disease
Time of Update: 2021-09-29
In observational studies, the relationship between the life-long level of female sex hormones and PD was extensively explored through alternative measures of self-reported menarche age and menopausal age .
-
Mov Disord: In Parkinson's patients, how does the mortality rate change over time?
Time of Update: 2021-09-29
After adjusting for age, sex, and time after diagnosis, compared with people without PD (5% per year; 95% CI: 3%-6%), the mortality rate of PD patients decreased more from 2007 to 2016.
-
Mov Disord: In the mentally related symptoms of Parkinson's patients, the serotonin and dopamine production system is the "culprit"?
Time of Update: 2021-09-29
They conducted a cross-sectional study that combined clinical and dual-tracer positron emission tomography (PET) neuroimaging methods, using dopamine radioligand ([11 C]DASB) reuptake, in different courses of Pa Among patients with Kinsen's disease (ie short course of disease without medicine (n = 27, 0-2 years course), with apathy (n = 14) or none (n = 13); moderate course (n = 15, 4) -7 years disease course) and long disease course, patients without dementia (n=15, 8-10 years disease course)) .
-
Mov Disord: Xiangya Hospital: Neurofilament light chain protein can effectively predict ataxia
Time of Update: 2021-09-29
However, a comprehensive meta-analysis has not been conducted to evaluate the potential role of NfL as a biomarker in predicting the occurrence of disease or symptoms, measuring disease severity, tracking disease progression, and monitoring treatment response to genetic ataxia .